Publicaciones en colaboración con investigadores/as de Hôpital Européen Georges-Pompidou (11)

2023

  1. Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial Carcinoma

    European Urology

2021

  1. Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial

    The Lancet Oncology, Vol. 22, Núm. 4, pp. 525-537

2020

  1. Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial

    Cancer, Vol. 126, Núm. 18, pp. 4156-4167

  2. Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study

    The Lancet Oncology, Vol. 21, Núm. 11, pp. 1513-1525

2019

  1. Vinflunine in the treatment of relapsed metastatic urothelial cancer: A systematic review and meta-analysis of real-world series

    Critical Reviews in Oncology/Hematology, Vol. 140, pp. 80-87

2018

  1. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial

    The Lancet, Vol. 391, Núm. 10122, pp. 748-757

  2. Cabozantinib, a new standard of care for patients with advanced renal cell carcinoma and bone metastases? Subgroup analysis of the METEOR trial

    Journal of Clinical Oncology

2017

  1. Cabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer: A randomized phase III trial - FIRSTANA

    Journal of Clinical Oncology, Vol. 35, Núm. 28, pp. 3189-3197

2015

  1. Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma

    British Journal of Cancer, Vol. 113, Núm. 1, pp. 12-19

2014

  1. Angiogenesis inhibitor therapies for advanced renal cell carcinoma: Toxicity and treatment patterns in clinical practice from a global medical chart review

    International Journal of Oncology, Vol. 44, Núm. 1, pp. 5-16

  2. Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer

    Journal of Clinical Oncology, Vol. 32, Núm. 2, pp. 76-82